According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The launch of Journavx represents Vertex’s entry into the pain management market, a move that could significantly diversify its revenue streams. The non-opioid nature of Journavx is expected to ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Journavx (suzetrigine), Vertex’s non-opioid NaV1.8 pain signal inhibitor, for the treatment of moderate-to-severe acute pain, was approved by the FDA in January 2025. At the fourth-quarter ...

The stock’s price increase is mainly because the company gained approval for two new products, its novel non-opioid pain medicine Journavx (suzetrigine ... in price. Vertex holds a dominant ...